Hypofractionated reirradiation for recurrent malignant glioma

Henke, Guido; Paulsen, Frank; Steinbach, Joachim P.; Ganswindt, Ute; Isijanov, Hana; Kortmann, Rolf‐Dieter; Bamberg, M.; Belka, Claus

doi:10.1007/s00066-009-1969-9

Cited by 66 publications

(50 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median length of survival for patients with high-grade primary glial tumors ranges from 11 to 33 months after initial diagnosis, with a mean survival time of 7 months following recurrence. 2,3 The failure of current approaches in the treatment of malignant glioma has been attributed to the existence of a subpopulation of cancer cells known as malignant glioma stem cells, which have the ability to withstand chemotherapeutics and ionizing radiation because of their unique properties of high antiapoptotic protein expression, high ABC pump expression, and a remarkable capacity for DNA repair. [4][5][6] Traditional therapies, such as DNA alkylating or methylating drugs, along with radiation, have poor efficacy against these types of cells.…”

Section: Introductionmentioning

confidence: 99%

Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles

Orza

Şoriţău²,

Tomuleasa³

et al. 2013

IJN

View full text Add to dashboard Cite

Abstract:The low rate of survival for patients diagnosed with glioblastoma may be attributed to the existence of a subpopulation of cancer stem cells. These stem cells have certain properties that enable them to resist chemotherapeutic agents and ionizing radiation. Herein, we show that temozolomide-loaded gold nanostructures are efficient in reducing chemoresistance and destroy 82.7% of cancer stem cells compared with a 42% destruction rate using temozolomide alone. Measurements of in vitro cytotoxicity and apoptosis indicate that combination with gold facilitated the ability of temozolomide, an alkylating drug, to alter the resistance of these cancer stem cells, suggesting a new chemotherapy strategy for patients diagnosed with inoperable recurrent malignant glioma.

show abstract

Section: Introductionmentioning

confidence: 99%

Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles

Orza

Şoriţău²,

Tomuleasa³

et al. 2013

IJN

View full text Add to dashboard Cite

show abstract

“…Modifications of radiotherapy aiming to improve survival or the quality of life of the patients have been proposed, e.g. hypofractionation, reduction of the dose or adaptation of the field size [24][25][26][27][28][29][30][31]. We analyzed whether it is possible to use the findings in MRIs during (chemo)radiotherapy as a predictor for the clinical course and for early prognostic stratification of patients.…”

Section: Discussionmentioning

confidence: 99%

MRI during radiotherapy of glioblastoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The dataset was collected from four different hospitals, namely the University Hospital of Leipzig (Germany) (n = 64 patients), the University Hospital of Tübingen (Germany) (n = 31 patients), the Cantonal Hospital of St. Gallen (Switzerland) (n = 13 patients) and the University Hospital of Maastricht (The Netherlands) (n = 57 patients). Characteristics and outcome of the patients from Leipzig, Tübingen and St. Gallen have already been published [10][11][12]. Of note, a significant proportion of the re-irradiated patients also underwent ReOP.…”

Section: Patient Cohortsmentioning

confidence: 99%

Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model

et al. 2015

Self Cite

View full text Add to dashboard Cite

We aimed to compare two different salvage treatment strategies for relapsed high-grade glioma (HGG) patients by means of a new prognostic model. A simplified version of the so-called HGG-Immuno RPA model estimates the prognosis of relapsed HGG patients and distinguishes three different prognostic classes (I = good, II = intermediate, III = poor). The model has been constructed with a cohort of 117 patients whose salvage treatment consisted of re-operation followed by dendritic cell vaccination (ReOP ? DCV). However, using only the predictors histology, age and performance status, the simplified HGG-Immuno RPA model is basically independent from treatment. In the present study we applied the simplified model to the cohort used to construct the original HGG-Immuno RPA model and another cohort of 165 patients who underwent re-irradiation (ReRT) at relapse. Then, we compared the outcomes achieved by the two different salvage treatments in each prognostic class. The model predicted good, intermediate and poor prognosis for 11, 31 and 75 patients of the ReOP ? DCV cohort and for 20, 39 and 106 patients of the ReRT cohort, respectively. Neither of the two strategies was superior to the other. In the groups with good, intermediate and poor prognosis 12-months survival rates were 73, 59 and 25 % after ReOP ? DCV and 72, 36 and 23 % after ReRT, respectively. Being easy to handle and independent from treatment, the aforementioned model is useful for therapeutic decisions. ReRT and ReOP ? DVC seem to be equally effective. The choice of salvage treatment should be based on the expected side effects.

show abstract

Hypofractionated reirradiation for recurrent malignant glioma

Abstract: Hypofractionated reirradiation with 20 Gy given over 1 week is a practicable and well-tolerated treatment option for patients with recurrent malignant glioma. The overall survival was comparable to the reported outcomes from other series including those with longer treatment protocols.

Cited by 66 publications

References 46 publications

Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles

Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles

MRI during radiotherapy of glioblastoma

Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model

Contact Info

Product

Resources

About